<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: indebtedness could limit cash flow", fill: "#004b49"},
{source: "5: indebtedness could limit cash flow", target: "5: operations", fill: "#004b49"},
{source: "5: operations", target: "5: could adversely affect", fill: "#004b49"},
{source: "5: could adversely affect", target: "5: service debt", fill: "#004b49"},
{source: "5: service debt", target: "5: additional financing", fill: "#004b49"},
{source: "5: additional financing", target: "5: necessary", fill: "#004b49"},
{source: "5: indebtedness could limit cash flow", target: "7: additional borrowing", fill: "#cc4e5c"},
{source: "7: additional borrowing", target: "7: capacity under", fill: "#cc4e5c"},
{source: "7: capacity under", target: "7: facility", fill: "#cc4e5c"},
{source: "7: facility", target: "7: outstanding letters", fill: "#cc4e5c"},
{source: "7: additional borrowing", target: "8: obligations adversely affect", fill: "#ff4f00"},
{source: "8: obligations adversely affect", target: "8: operations", fill: "#ff4f00"},
{source: "8: operations", target: "8: adequate sources", fill: "#ff4f00"},
{source: "8: adequate sources", target: "8: capital debt service", fill: "#ff4f00"},
{source: "8: capital debt service", target: "8: capital expenditures", fill: "#ff4f00"},
{source: "8: capital expenditures", target: "8: cash flow from", fill: "#ff4f00"},
{source: "8: cash flow from", target: "8: operations will", fill: "#ff4f00"},
{source: "8: operations will", target: "8: debt which may", fill: "#ff4f00"},
{source: "8: debt which may", target: "8: borrow additional funds", fill: "#ff4f00"},
{source: "8: borrow additional funds", target: "8: purpose restructure", fill: "#ff4f00"},
{source: "8: purpose restructure", target: "8: otherwise refinance", fill: "#ff4f00"},
{source: "8: obligations adversely affect", target: "12: indebtedness", fill: "#fffaf0"},
{source: "12: indebtedness", target: "12: additional", fill: "#fffaf0"},
{source: "12: additional", target: "12: flexibility", fill: "#fffaf0"},
{source: "12: flexibility", target: "12: competitive disadvantage relative", fill: "#fffaf0"},
{source: "12: competitive disadvantage relative", target: "12: competitors", fill: "#fffaf0"},
{source: "12: competitors", target: "12: with less indebtedness", fill: "#fffaf0"},
{source: "12: with less indebtedness", target: "12: general adverse economic regulatory", fill: "#fffaf0"},
{source: "12: general adverse economic regulatory", target: "12: industry conditions", fill: "#fffaf0"},
{source: "12: industry conditions", target: "12: cash flow", fill: "#fffaf0"},
{source: "12: indebtedness", target: "17: existing debt agreements limit", fill: "#ff6e4a"},
{source: "17: existing debt agreements limit", target: "19: Borrowings ", fill: "#01796f"},
{source: "19: Borrowings ", target: "19: senior secured", fill: "#01796f"},
{source: "19: senior secured", target: "19: facility", fill: "#01796f"},
{source: "19: facility", target: "19: accounts receivable under", fill: "#01796f"},
{source: "19: accounts receivable under", target: "19: receivables securitization", fill: "#01796f"},
{source: "19: receivables securitization", target: "19: agreements", fill: "#01796f"},
{source: "19: agreements", target: "19: based upon variable rates", fill: "#01796f"},
{source: "19: based upon variable rates", target: "19: interest which could", fill: "#01796f"},
{source: "19: interest which could", target: "19: higher expense", fill: "#01796f"},
{source: "19: higher expense", target: "19: interest rates", fill: "#01796f"},
{source: "19: Borrowings ", target: "21: Therefore ", fill: "#1a2421"},
{source: "21: Therefore ", target: "21: in LIBOR ", fill: "#1a2421"},
{source: "21: in LIBOR ", target: "21: would increase", fill: "#1a2421"},
{source: "21: would increase", target: "21: interest payment", fill: "#1a2421"},
{source: "21: interest payment", target: "21: obligations", fill: "#1a2421"},
{source: "21: obligations", target: "21: outstanding loans increase", fill: "#1a2421"},
{source: "21: outstanding loans increase", target: "21: receivables", fill: "#1a2421"},
{source: "21: receivables", target: "21: securitization program fee payments", fill: "#1a2421"},
{source: "21: securitization program fee payments", target: "21: financial condition", fill: "#1a2421"},
{source: "21: Therefore ", target: "35: general economic conditions", fill: "#e3ff00"},
{source: "35: general economic conditions", target: "35: major industries", fill: "#e3ff00"},
{source: "35: major industries", target: "35: adversely affect", fill: "#e3ff00"},
{source: "35: adversely affect", target: "35: pharmacy sales", fill: "#e3ff00"},
{source: "35: pharmacy sales", target: "35: consumer buying practices", fill: "#e3ff00"},
{source: "35: consumer buying practices", target: "35: frontend products", fill: "#e3ff00"},
{source: "35: frontend products", target: "35: profitability", fill: "#e3ff00"},
{source: "35: general economic conditions", target: "36: operations", fill: "#009f6b"},
{source: "36: operations", target: "36: major industries", fill: "#009f6b"},
{source: "36: major industries", target: "36: general economic conditions", fill: "#009f6b"},
{source: "36: general economic conditions", target: "36: would adversely affect", fill: "#009f6b"},
{source: "36: would adversely affect", target: "36: operations financial condition", fill: "#009f6b"},
{source: "36: operations financial condition", target: "36: cash flows", fill: "#009f6b"},
{source: "36: cash flows", target: "36: interest payments on", fill: "#009f6b"},
{source: "36: operations", target: "48: dollar value", fill: "#8601af"},
{source: "48: dollar value", target: "48: prescription drugs", fill: "#8601af"},
{source: "48: prescription drugs", target: "48: single supplier", fill: "#8601af"},
{source: "48: single supplier", target: "48: runs through", fill: "#8601af"},
{source: "48: dollar value", target: "62: adverse trend", fill: "#f0fff0"},
{source: "62: adverse trend", target: "62: drugstore retailing", fill: "#f0fff0"},
{source: "62: drugstore retailing", target: "62: been initiatives", fill: "#f0fff0"},
{source: "62: been initiatives", target: "62: rapid growth", fill: "#f0fff0"},
{source: "62: rapid growth", target: "62: prescription processors", fill: "#f0fff0"},
{source: "62: adverse trend", target: "65: medications", fill: "#138808"},
{source: "65: medications", target: "65: prescriptions", fill: "#138808"},
{source: "65: medications", target: "74: reimbursement", fill: "#ff4040"},
{source: "74: reimbursement", target: "74: prescription", fill: "#ff4040"},
{source: "74: reimbursement", target: "START_HERE", fill: "#ff4040"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Household Products</td>
    </tr>
    <tr>
      <td>Personal Products</td>
    </tr>
    <tr>
      <td>Leisure Products</td>
    </tr>
    <tr>
      <td>Paper Products</td>
    </tr>
    <tr>
      <td>Household and Personal Products</td>
    </tr>
    <tr>
      <td>Building Products</td>
    </tr>
    <tr>
      <td>Agricultural Products</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_ID">Facility ID</a></td>
      <td>The facility ID number, also called a FIN or facility identifier, is a unique integer number of one to six digits, assigned by the U.S. Federal Communications Commission (FCC) Media Bureau to each broadcast station in the FCC Consolidated Database System (CDBS) and Licensing and Management System (LMS) databases, among others.\nBecause CDBS includes information about foreign stations which are notified to the U.S. under the terms of international frequency coordination agreements, FINs are also assigned to affected foreign stations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_facility">Health facility</a></td>
      <td>A health facility is, in general, any location where healthcare is provided. Health facilities range from small clinics and doctor's offices to urgent care centers and large hospitals with elaborate emergency rooms and trauma centers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Telecommunications_facility">Telecommunications facility</a></td>
      <td>In telecommunications, a facility is defined by Federal Standard 1037C as:\n\nA fixed, mobile, or transportable structure, including (a) all installed electrical and electronic wiring, cabling, and equipment and (b) all supporting structures, such as utility, ground network, and electrical supporting structures.\nA network-provided service to users or the network operating administration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hillside_Facility">Hillside Facility</a></td>
      <td>The Hillside Facility, also called the Hillside Support Facility or the Hillside Maintenance Complex, is a maintenance facility of the Long Island Rail Road (LIRR) in Jamaica, Queens, New York City. The Hillside facility was built between 1984 and 1991 on the grounds of a section of Holban Yard, a railroad freight yard.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Discounted_cash_flow">Discounted cash flow</a></td>
      <td>In finance, discounted cash flow (DCF) analysis is a method of valuing a security, project, company, or asset using the concepts of the time value of money. \nDiscounted cash flow analysis is widely used in investment finance, real estate development, corporate financial management and patent valuation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Free_cash_flow_to_equity">Free cash flow to equity</a></td>
      <td>In corporate finance, free cash flow to equity (FCFE) is a metric of how much cash can be distributed to the equity shareholders of the company as dividends or stock buybacks—after all expenses, reinvestments, and debt repayments are taken care of. It is also referred to as the levered free cash flow or the flow to equity (FTE).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cash-flow_diagram">Cash-flow diagram</a></td>
      <td>A cash-flow diagram  is a financial tool used to represent the cashflows associated with a security,  "project", or business.\nAs per the graphics, cash flow diagrams are widely used in structuring and analyzing securities, particularly swaps.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Net_present_value">Net present value</a></td>
      <td>The net present value (NPV) or net present worth (NPW) applies to a series of cash flows occurring at different times. The present value of a cash flow depends on the interval of time between now and the cash flow.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenuptial_agreement">Prenuptial agreement</a></td>
      <td>A prenuptial agreement, antenuptial agreement, or premarital agreement (commonly referred to as a prenup), is a written contract entered into by a couple prior to marriage or a civil union that enables them to select and control many of the legal rights they acquire upon marrying, and what happens when their marriage eventually ends by death or divorce. Couples enter into a written prenuptial agreement to supersede many of the default marital laws that would otherwise apply in the event of divorce, such as the laws that govern the division of property, retirement benefits, savings, and the right to seek alimony (spousal support) with agreed-upon terms that provide certainty and clarify their marital rights.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minsk_agreements">Minsk agreements</a></td>
      <td>The Minsk agreements were a series of international agreements which sought to end the war in the Donbas region of Ukraine. The first, known as the Minsk Protocol, was drafted in 2014 by the Trilateral Contact Group on Ukraine, consisting of Ukraine, Russia, and the Organization for Security and Co-operation in Europe (OSCE), with mediation by the leaders of France and Germany in the so-called Normandy Format.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Four_Agreements">The Four Agreements</a></td>
      <td>The Four Agreements: A Practical Guide to Personal Freedom is a self-help book by bestselling author Don Miguel Ruiz with Janet Mills. The book offers a code of conduct claiming to be based on ancient Toltec wisdom that advocates freedom from self-limiting beliefs that may cause suffering and limitation in a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-disclosure_agreement">Non-disclosure agreement</a></td>
      <td>A non-disclosure agreement (NDA), also known as a confidentiality agreement (CA), confidential disclosure agreement (CDA), proprietary information agreement (PIA), secrecy agreement (SA), or non-disparagement agreement, is a legal contract or part of a contract between at least two parties that outlines confidential material, knowledge, or information that the parties wish to share with one another for certain purposes, but wish to restrict access to. Doctor–patient confidentiality (physician–patient privilege), attorney–client privilege, priest–penitent privilege and bank–client confidentiality agreements are examples of NDAs, which are often not enshrined in a written contract between the parties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/TRIPS_Agreement">TRIPS Agreement</a></td>
      <td>The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacy">Pharmacy</a></td>
      <td>Pharmacy is the clinical health science that links medical science with chemistry and it is charged with the discovery, production, disposal, safe and effective use, and control of medications and drugs. The practice of pharmacy requires excellent knowledge of drugs, their mechanism of action, side effects, interactions, mobility and toxicity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prescription_drug">Prescription drug</a></td>
      <td>A prescription drug (also prescription medication or prescription medicine) is a pharmaceutical drug that legally requires a medical prescription to be dispensed. In contrast, over-the-counter drugs can be obtained without a prescription.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_prescription">Medical prescription</a></td>
      <td>A prescription, often abbreviated ℞ or Rx, is a formal communication from a physician or other registered health-care professional to a pharmacist, authorizing them to dispense a specific prescription drug for a specific patient. Historically, it was a physician's instruction to an apothecary listing the materials to be compounded into a treatment—the symbol ℞ (a capital letter R, crossed to indicate abbreviation) comes from the first word of a medieval prescription, Latin: Recipere ("Take thou"), that gave the list of the materials to be compounded.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statute_of_limitations">Statute of limitations</a></td>
      <td>A statute of limitations, known in civil law systems as a prescriptive period, is a law passed by a legislative body to set the maximum time after an event within which legal proceedings may be initiated. In the United States, a government agency is permitted by the Congress to create under federal regulations its own statute of limitations.When the time which is specified in a statute of limitations runs out, a claim might no longer be filed or, if it is filed, it may be subject to dismissal if the defense against that claim is raised that the claim is time-barred as having been filed after the statutory limitations period.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prescription_charges">Prescription charges</a></td>
      <td>Charges for prescriptions for medicines and some medical appliances are payable by adults in England under the age of 60, although a majority are exempt for various reasons. Charges were abolished in NHS Wales in 2007, Health and Social Care in Northern Ireland in 2010 and by NHS Scotland in 2011.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reimbursement">Reimbursement</a></td>
      <td>Reimbursement is the act of compensating someone for an out-of-pocket expense by giving them an amount of money equal to what was spent.Companies, governments and nonprofit organizations may compensate their employees or officers for necessary and reasonable expenses; under US\nlaw, these expenses may be deducted from taxes by the organization and treated as untaxed income for the recipient provided that accountability conditions are met. UK law provides for deductions for travel and subsistence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_mileage_reimbursement_rate">Business mileage reimbursement rate</a></td>
      <td>The business mileage reimbursement rate is an optional standard mileage rate used in the United States for purposes of computing the allowable business deduction, for Federal income tax purposes under the Internal Revenue Code, at 26 U.S.C. § 162, for the business use of a vehicle. Under the law, the taxpayer for each year is generally entitled to deduct either the actual expense amount, or an amount computed using the standard mileage rate, whichever is greater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ERISA_reimbursement">ERISA reimbursement</a></td>
      <td>In the United States, ERISA reimbursement refers to the efforts of an ERISA Plan administrator (an insurer) to obtain repayment from an insured person who had previously received payments for personal injury medical bills.When an insurer pays a injury claim to someone, the insurer can seize cash settlements from whoever caused the injury. This “right of reimbursement” is essentially a subrogation claim.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitation_(healthcare)">Capitation (healthcare)</a></td>
      <td>Capitation is a payment arrangement for health care service providers. It pays a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fee_Reimbursement_Scheme_(Andhra_Pradesh)">Fee Reimbursement Scheme (Andhra Pradesh)</a></td>
      <td>The Fee Reimbursement Scheme (also known as the Post-matric Scholarship Scheme) is a student education sponsorship programme of the Government of Andhra Pradesh. It supports students from lower economic strata in the state.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>RITE AID CORP      Item 1A   Risk Factors       Factors Affecting our Future Prospects       Set forth below is a description of <font color="blue">certain risk factors which</font> we believe     may be relevant to an understanding of us and our business</td>
    </tr>
    <tr>
      <td><font color="blue">Securityholders     </font>are cautioned that these and other <font color="blue">factors may affect future performance</font> and     cause actual results to <font color="blue">differ from</font> those which may, from time to time, be     anticipated</td>
    </tr>
    <tr>
      <td>”       Risks Related to Our Financial Condition       We are <font color="blue">highly leveraged</font></td>
    </tr>
    <tr>
      <td>Our substantial <font color="blue"><font color="blue">indebtedness</font> could limit <font color="blue">cash flow</font></font>     available for our <font color="blue">operations</font> and <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our ability to     <font color="blue">service debt</font> or obtain <font color="blue"><font color="blue">additional</font> financing</font> if <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>We had, as of March 4, 2006, dlra3dtta1 billion of <font color="blue">outstanding <font color="blue">indebtedness</font></font> and     stockholders’ equity of dlra1cmam606dtta9 million</td>
    </tr>
    <tr>
      <td>We also had <font color="blue"><font color="blue">additional</font> borrowing</font>     <font color="blue">capacity under</font> our revolving credit <font color="blue">facility</font> of dlra1cmam100dtta3 million at that     time, net of <font color="blue">outstanding letters</font> of credit of dlra115dtta7 million</td>
    </tr>
    <tr>
      <td>Our debt     <font color="blue"><font color="blue">obligations</font> <font color="blue"><font color="blue">adversely</font> affect</font></font> our <font color="blue">operations</font> in a number of ways and while we     believe  we have <font color="blue">adequate sources</font> of liquidity to meet our anticipated     <font color="blue">requirements</font> for working capital, debt service and <font color="blue">capital expenditures</font>     through fiscal year 2007, there can be no assurance that our <font color="blue"><font color="blue">cash flow</font> from</font>     <font color="blue">operations</font> will be sufficient to service our debt, which may require us to     <font color="blue">borrow <font color="blue">additional</font> funds</font> for that purpose, <font color="blue">restructure</font> or <font color="blue">otherwise refinance</font>     our debt</td>
    </tr>
    <tr>
      <td>Our <font color="blue">high level</font> of <font color="blue"><font color="blue">indebtedness</font> will continue</font> to restrict our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Among other things, our <font color="blue">indebtedness</font> will:       ·       limit our ability to obtain <font color="blue"><font color="blue">additional</font> financing</font>;       ·       limit our <font color="blue">flexibility</font> in planning for, or reacting to, changes in     the markets in which we compete;       ·       place us at a <font color="blue"><font color="blue">competitive</font> disadvantage relative</font> to our <font color="blue">competitors</font>     with less <font color="blue">indebtedness</font>;       ·       render us more vulnerable to general adverse economic, <font color="blue">regulatory</font>     and <font color="blue">industry conditions</font>; and       ·       require us to dedicate a substantial portion of our <font color="blue">cash flow</font> to     service our debt</td>
    </tr>
    <tr>
      <td>Our  ability  to make <font color="blue">payments on</font> our <font color="blue">debt depends upon</font> our ability to     <font color="blue">substantially improve</font> our operating performance, which is subject to general     economic and <font color="blue"><font color="blue">competitive</font> conditions</font> and to financial, business and other     factors,  many  of  which we <font color="blue">cannot control</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">cash flow</font> from</font> our     operating <font color="blue">activities</font> is insufficient, we may take <font color="blue">certain actions</font>, including     delaying  or  reducing  capital  or  other expenditures, attempting to     <font color="blue">restructure</font> or refinance our debt, selling assets or <font color="blue">operations</font> or seeking     <font color="blue">additional</font> equity capital</td>
    </tr>
    <tr>
      <td>We may be unable to take any of these <font color="blue">actions on</font>     satisfactory terms or in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Further, any of these <font color="blue">actions may</font>     not be sufficient to allow us to service our  <font color="blue">debt <font color="blue">obligations</font></font> or may have     an <font color="blue">adverse impact on</font> our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">existing debt <font color="blue">agreements</font> limit</font> our     ability to take certain of these actions</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">earn enough</font> to pay     our debts or to <font color="blue">successfully</font> undertake any of these <font color="blue">actions could</font> have a     material adverse effect on us</td>
    </tr>
    <tr>
      <td><font color="blue">Borrowings </font>under our <font color="blue">senior secured</font> credit <font color="blue">facility</font> and expenses related to     the sale of our <font color="blue">accounts receivable under</font> our <font color="blue"><font color="blue">receivables</font> securitization</font>     <font color="blue">agreements</font> are <font color="blue">based upon <font color="blue">variable rates</font></font> of interest, which could result in     <font color="blue">higher expense</font> in the event of increases in <font color="blue"><font color="blue">interest rate</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>dlra534 million of our <font color="blue">outstanding <font color="blue">indebtedness</font></font> as of March 4,     2006 bears an <font color="blue">interest rate</font> that <font color="blue">varies <font color="blue">depending upon</font></font> LIBOR If we borrow     <font color="blue">additional</font> amounts under our senior credit <font color="blue">facility</font>, the <font color="blue">interest rate</font> on     those  borrowings will also vary <font color="blue">depending upon</font> LIBOR Further, we pay     ongoing       11     ______________________________________________________________________       <font color="blue">program fees under</font> our <font color="blue"><font color="blue">receivables</font> securitization</font> <font color="blue">agreements</font> that vary     <font color="blue">depending upon</font> <font color="blue">LIBOR If LIBOR </font>rises, the <font color="blue"><font color="blue">interest rate</font>s</font> on outstanding debt     and the <font color="blue">program fees under</font> our <font color="blue"><font color="blue">receivables</font> securitization</font> program will     increase</td>
    </tr>
    <tr>
      <td><font color="blue">Therefore </font>an increase <font color="blue">in LIBOR </font><font color="blue">would increase</font> our <font color="blue">interest payment</font>     <font color="blue">obligations</font>  under  these  outstanding loans, increase our <font color="blue">receivables</font>     <font color="blue">securitization program fee payments</font> and have a negative effect on our cash     flow and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We currently do not maintain any hedging     contracts that <font color="blue">would limit</font> our exposure to <font color="blue">variable rates</font> of interest</td>
    </tr>
    <tr>
      <td>The covenants in our <font color="blue">outstanding <font color="blue">indebtedness</font></font> impose restrictions that may     limit our operating and financial <font color="blue">flexibility</font></td>
    </tr>
    <tr>
      <td>The covenants in the <font color="blue">instruments</font> that govern our <font color="blue">outstanding <font color="blue">indebtedness</font></font>     limit our ability to:       ·       <font color="blue">incur liens</font> and debt;       ·       <font color="blue">pay dividends</font>;       ·       make <font color="blue">redemptions</font> and <font color="blue">repurchases</font> of <font color="blue">capital stock</font>;       ·       make loans and <font color="blue">investments</font>;       ·       prepay, redeem or <font color="blue">repurchase debt</font>;       ·         engage  in  mergers,  <font color="blue">consolidations</font>,  assets  <font color="blue">dispositions</font>,     sale-leaseback transactions and <font color="blue">affiliate transactions</font>;       ·       change our business;       ·       amend some of our debt and other material <font color="blue">agreements</font>;       ·       issue and sell <font color="blue">capital stock</font> of <font color="blue">subsidiaries</font>;       ·       restrict <font color="blue">distribution</font>s from <font color="blue">subsidiaries</font>; and       ·       <font color="blue">grant negative pledges</font> to other <font color="blue">creditors</font></td>
    </tr>
    <tr>
      <td>In  addition,  if we have less than dlra100dtta0 million available under our     revolving credit <font color="blue">facility</font>, we will be subject to <font color="blue">certain financial covenant</font>     ratios</td>
    </tr>
    <tr>
      <td>If we are unable to meet the terms of the <font color="blue">financial covenants</font> or if     we breach any of these covenants, a <font color="blue">default could</font> result under one or more     of these <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>A default, if not waived by our lenders, could result     in the <font color="blue">acceleration</font> of our <font color="blue">outstanding <font color="blue">indebtedness</font></font> and cause our debt to     <font color="blue">become immediately due</font> and payable</td>
    </tr>
    <tr>
      <td>If <font color="blue">acceleration</font> occurs, we would not be     able to repay our debt and it is unlikely that we would be able to borrow     sufficient <font color="blue">additional</font> funds to <font color="blue">refinance such debt</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">new financing</font> is     made available to us, it may not be <font color="blue">available on terms</font> acceptable to us</td>
    </tr>
    <tr>
      <td>If     we obtain <font color="blue">modifications</font> of our <font color="blue">agreements</font>, or are required to obtain waivers     of <font color="blue">defaults</font>, we <font color="blue">may incur <font color="blue">significant</font> fees</font> and <font color="blue">transaction costs</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Operations       We  need to continue to improve our <font color="blue">operations</font> in order to improve our     financial  condition, but our <font color="blue">operations</font> will not improve if we cannot     continue to <font color="blue"><font color="blue">effective</font>ly</font> implement our business strategy or if our strategy     is <font color="blue">negatively affected by <font color="blue">general economic conditions</font></font></td>
    </tr>
    <tr>
      <td>We  have  not  yet  achieved the <font color="blue">sales productivity level</font> of our major     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We believe that improving the sales of <font color="blue">existing stores</font> is     important to <font color="blue">improving <font color="blue">profitability</font></font> and operating <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>If we are not     successful  in  <font color="blue">implementing</font>  our  strategy, or if our strategy is not     <font color="blue">effective</font>, we may not be able to improve our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, any     adverse  change in <font color="blue">general economic conditions</font> or <font color="blue">major industries</font> can     <font color="blue"><font color="blue">adversely</font> affect</font> <font color="blue">drug benefit</font> plans and reduce our <font color="blue">pharmacy sales</font> or can     <font color="blue"><font color="blue">adversely</font> affect</font>       12     ______________________________________________________________________       <font color="blue">consumer buying practices</font> and reduce our sales of front-end products, and     cause  a decrease in our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Failure to continue to improve     <font color="blue">operations</font> or a decline in <font color="blue">major industries</font> or <font color="blue">general economic conditions</font>     would <font color="blue"><font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font>, <font color="blue">financial condition</font> and     <font color="blue">cash flow</font>s and our ability to make principal or interest <font color="blue">payments on</font> our     debt</td>
    </tr>
    <tr>
      <td>Our new store and <font color="blue">store relocation development program</font> requires entering     <font color="blue">construction</font> and <font color="blue">development <font color="blue">commitments</font></font> and <font color="blue">occasionally purchasing land</font>     that will not be utilized for <font color="blue"><font color="blue">several years</font> which may limit</font> our financial     <font color="blue">flexibility</font></td>
    </tr>
    <tr>
      <td>We will enter into <font color="blue">significant</font> <font color="blue">construction</font> and <font color="blue">development <font color="blue">commitments</font></font> as     part of our new store and <font color="blue">store relocation development program</font></td>
    </tr>
    <tr>
      <td>Also, we     <font color="blue">will occasionally</font> make <font color="blue">capital expenditures</font> to acquire land that may not be     used for <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>Even if there are <font color="blue"><font color="blue">significant</font> negative economic</font> or     <font color="blue"><font color="blue">competitive</font> developments</font> in our industry, <font color="blue">financial condition</font> or the regions     where we have made these <font color="blue">commitments</font>, we are obligated to fulfill these     <font color="blue">commitments</font></td>
    </tr>
    <tr>
      <td>Further, if we <font color="blue">subsequently dispose</font> of the property that we     acquire, we may receive less than our <font color="blue">purchase price</font> or the <font color="blue">net book value</font>     of such property, which may result in <font color="blue">financial loss</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> our <font color="blue">management team</font>, and the loss of their services     could have a material adverse effect on our business and the results of our     <font color="blue">operations</font> or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The success of our business is <font color="blue">materially dependent upon</font> the continued     services of our executive <font color="blue">management team</font></td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">key personnel could</font>     have a material adverse effect on the results of our <font color="blue">operations</font>, financial     condition or <font color="blue">cash flow</font>s</td>
    </tr>
    <tr>
      <td>Additionally, we <font color="blue">cannot assure</font> you that we will be     able to attract or retain other <font color="blue">skilled personnel</font> in the future</td>
    </tr>
    <tr>
      <td>We  are substantially <font color="blue">dependent on</font> a <font color="blue">single supplier</font> of <font color="blue">pharmaceutical</font>     products to <font color="blue">sell products</font> to us on satisfactory terms</td>
    </tr>
    <tr>
      <td>A <font color="blue">disruption</font> in this     <font color="blue">relationship</font>  may have a negative effect on our results of <font color="blue">operations</font>,     <font color="blue">financial condition</font> and <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>We obtain approximately 94prca of the <font color="blue">dollar value</font> of our <font color="blue"><font color="blue">prescription</font> drugs</font>     from a <font color="blue">single supplier</font>, McKesson, pursuant to a contract that <font color="blue">runs through</font>     March 2009</td>
    </tr>
    <tr>
      <td>Pharmacy sales represented approximately 63dtta2prca of our total     sales during fiscal 2006, and, therefore, our <font color="blue">relationship</font> with McKesson is     important  to us</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> <font color="blue">disruption</font>s in our <font color="blue">relationship</font> with     McKesson would make it <font color="blue">difficult</font> for us to continue to operate our business     until we executed a <font color="blue">replacement strategy</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we     would be able to find a <font color="blue">replacement supplier on</font> a <font color="blue">timely basis</font> or that such     <font color="blue">supplier would</font> be able to fulfill our <font color="blue">demands on</font> similar terms, <font color="blue">which would</font>     have a material adverse effect on our results of <font color="blue">operations</font>, financial     condition and <font color="blue">cash flow</font>s</td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry       The markets in which we operate are very <font color="blue">competitive</font> and <font color="blue">further increases</font>     in <font color="blue">competition</font> <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> us</td>
    </tr>
    <tr>
      <td>We face intense <font color="blue">competition</font> with local, regional and <font color="blue">national companies</font>,     including  other  drugstore  chains,  <font color="blue">independently</font>  owned <font color="blue">drugstores</font>,     supermarkets, mass merchandisers, discount stores, dollar stores and mail     order pharmacies</td>
    </tr>
    <tr>
      <td>Our industry also faces growing <font color="blue">competition</font> from companies     who <font color="blue">import drugs directly from</font> other countries, such as Canada</td>
    </tr>
    <tr>
      <td>We may not     be  able  to  <font color="blue"><font color="blue">effective</font>ly</font> compete against them because our existing or     potential  <font color="blue">competitors</font> may have financial and other resources that are     superior to ours</td>
    </tr>
    <tr>
      <td>In addition, we may be at a <font color="blue">competitive</font> disadvantage     because we are more <font color="blue">highly leveraged</font> than our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>The ability of     our stores to achieve <font color="blue">profitability</font> depends on their ability to achieve a     <font color="blue">critical mass</font> of customers</td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue">continued consolidation</font> of     the drugstore industry will further increase <font color="blue">competitive</font> pressures in the     industry</td>
    </tr>
    <tr>
      <td>As <font color="blue"><font color="blue">competition</font> increases</font>, a <font color="blue"><font color="blue">significant</font> increase</font> in general     <font color="blue">pricing pressures could</font> occur, <font color="blue">which would</font> require us to increase our sales     volume and to sell       13     ______________________________________________________________________       <font color="blue">higher margin products</font> and services in order to remain <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that we will be able to continue <font color="blue"><font color="blue">effective</font>ly</font> to compete in     our markets or increase our <font color="blue">sales volume</font> in response to <font color="blue">further increased</font>     <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Drug benefit plan sponsors and <font color="blue"><font color="blue">third party payors</font> could</font> change their plan     <font color="blue"><font color="blue">eligibility</font> criteria</font> and <font color="blue">further encourage</font> or require the use of mail-order     <font color="blue"><font color="blue"><font color="blue">prescription</font>s</font> which could decrease</font> our sales and reduce our margins and have     a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse trend</font> for <font color="blue">drugstore retailing</font> has <font color="blue">been <font color="blue">initiatives</font></font> to contain     rising  healthcare  costs  leading  to  the <font color="blue">rapid growth</font> in mail-order     <font color="blue"><font color="blue">prescription</font> processors</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue"><font color="blue">prescription</font> <font color="blue">distribution</font></font> methods</font> have grown     in market share relative to <font color="blue">drugstores</font> as a result of the <font color="blue">rapid rise</font> in drug     costs experienced in <font color="blue">recent years</font> and are predicted to continue to rise</td>
    </tr>
    <tr>
      <td>Mail-order <font color="blue"><font color="blue"><font color="blue">prescription</font> <font color="blue">distribution</font></font> methods</font> are perceived <font color="blue">by employers</font> and     insurers as being <font color="blue">less costly than traditional <font color="blue">distribution</font> methods</font> and are     being encouraged, and, in some cases, required, <font color="blue">by third party pharmacy</font>     benefit  managers, employers and unions that <font color="blue">administer benefits</font></td>
    </tr>
    <tr>
      <td>As a     result,  some labor unions and employers are requiring, and others may     encourage or require, that their members or employees obtain <font color="blue">medications</font>     from mail-order pharmacies which offer drug <font color="blue"><font color="blue">prescription</font>s</font> at prices lower     than we are able to offer</td>
    </tr>
    <tr>
      <td>Another <font color="blue">adverse trend</font> for <font color="blue">drugstore retailing</font> has been for <font color="blue">drug benefit</font> plan     sponsors  and  third  party  payors  to  change their plan <font color="blue">eligibility</font>     <font color="blue">requirements</font> resulting in <font color="blue">fewer beneficiaries covered</font> and a reduction in the     number of <font color="blue"><font color="blue">prescription</font>s</font> allowed</td>
    </tr>
    <tr>
      <td>Mail-order <font color="blue"><font color="blue">prescription</font> <font color="blue">distribution</font></font> and <font color="blue">drug benefit</font> plan <font color="blue">eligibility</font>     changes have <font color="blue">negatively affected sales</font> for <font color="blue">traditional chain drug retailers</font>,     including us, in the <font color="blue">last few years</font> and we expect <font color="blue">such negative</font> effect to     continue in the future</td>
    </tr>
    <tr>
      <td>There can be no assurance that our efforts to offset     the effects of mail order and <font color="blue">eligibility</font> changes will be successful</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of <font color="blue">pharmacy drugs</font> is subject to <font color="blue"><font color="blue">government</font>al <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">continued conversion</font> of various <font color="blue"><font color="blue">prescription</font> drugs</font> to over-the-counter     <font color="blue">medications</font> may reduce our <font color="blue">pharmacy sales</font> and <font color="blue">customers may seek</font> to purchase     such <font color="blue">medications</font> at non-pharmacy stores</td>
    </tr>
    <tr>
      <td>Also, if the <font color="blue">rate at which new</font>     <font color="blue"><font color="blue">prescription</font> drugs</font> become available slows or if new <font color="blue"><font color="blue">prescription</font> drugs</font> that     are <font color="blue">introduced into</font> the <font color="blue">market fail</font> to achieve <font color="blue">popularity</font>, our pharmacy     sales may be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>The withdrawal of <font color="blue">certain drugs</font> from the     market or <font color="blue">concerns about</font> the safety or <font color="blue">effective</font>ness of <font color="blue">certain drugs</font> or     negative publicity surrounding certain categories of <font color="blue">drugs may also</font> have a     negative effect on our <font color="blue">pharmacy sales</font> or may cause shifts in our pharmacy or     front-end product mix</td>
    </tr>
    <tr>
      <td>For example, growth in late 2004 and 2005 was slowed     by the negative publicity surrounding certain arthritis <font color="blue">medications</font> and     other high-volume drugs, which <font color="blue"><font color="blue">adversely</font> affect</font>ed <font color="blue">pharmacy sales</font></td>
    </tr>
    <tr>
      <td>Changes in third party <font color="blue">reimbursement</font> levels for <font color="blue"><font color="blue">prescription</font> drugs</font> could     reduce our margins and have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Sales of <font color="blue"><font color="blue">prescription</font> drugs</font>, as a percentage of sales, and the percentage of     <font color="blue">prescription</font> sales reimbursed by third parties, have <font color="blue">been increasing</font> and we     expect them to continue to increase</td>
    </tr>
    <tr>
      <td>In fiscal 2006, sales of <font color="blue">prescription</font>     drugs represented 63dtta2prca of our sales and 93dtta9prca of all of the <font color="blue">prescription</font>     drugs that we sold were <font color="blue">with <font color="blue">third party payors</font></font></td>
    </tr>
    <tr>
      <td>During fiscal 2006, the top     five third-party payors accounted for approximately 31dtta0prca of our total     sales, the largest of which represented 8dtta9prca of our <font color="blue">total sales</font></td>
    </tr>
    <tr>
      <td>In fiscal     2006, approximately 11dtta4prca of our revenues were from state sponsored <font color="blue">Medicaid     </font>agencies,  the  largest  of which was less than 3prca of our <font color="blue">total sales</font></td>
    </tr>
    <tr>
      <td>Beginning  January  2006, a <font color="blue"><font color="blue">significant</font> amount</font> of our Medicaid related     <font color="blue"><font color="blue">prescription</font>s</font> moved to <font color="blue">coverage under</font> the new <font color="blue">Medicare Part D </font>plans</td>
    </tr>
    <tr>
      <td><font color="blue">After     </font>considering  this  shift in payor, we expect Medicaid related sales to     represent approximately 8prca of <font color="blue">total sales</font> in fiscal 2007</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font>     loss of third-party payor business could have a material adverse effect on     our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________       Third <font color="blue">party payors could reduce</font> the <font color="blue">levels at which</font> they <font color="blue">will reimburse us</font>     for the <font color="blue"><font color="blue">prescription</font> drugs</font> that we provide to their members</td>
    </tr>
    <tr>
      <td>Furthermore,     the <font color="blue">Medicare Part D </font>program, which went into effect January 1, 2006, has     <font color="blue">reimbursement</font>  levels  that  are  lower  than  the  previous  level of     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>There have been a number of <font color="blue">recent proposals</font> and <font color="blue"><font color="blue">enactment</font>s</font>     by  the  <font color="blue">Federal  </font><font color="blue">government</font>  and  various  states  to reduce <font color="blue">Medicaid     </font><font color="blue">reimbursement</font> levels in response to <font color="blue">budget problems</font>, some of <font color="blue">which propose</font>     to reduce <font color="blue">reimbursement</font> levels in the applicable states <font color="blue">significant</font>ly, and     we expect other similar proposals in the future</td>
    </tr>
    <tr>
      <td>If <font color="blue">third party payors</font>     reduce their <font color="blue">reimbursement</font> levels or if Medicare or state Medicaid programs     cover <font color="blue"><font color="blue">prescription</font> drugs</font> at lower <font color="blue">reimbursement</font> levels, our <font color="blue">margins on</font> these     sales  would be reduced, and the <font color="blue">profitability</font> of our business and our     results of <font color="blue">operations</font>, <font color="blue">financial condition</font> or <font color="blue">cash flow</font>s could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue"><font color="blue">government</font>al <font color="blue">regulations</font></font>, procedures and <font color="blue">requirements</font>; our     <font color="blue">noncompliance</font> or a <font color="blue">significant</font> <font color="blue">regulatory</font> change <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our     business, the results of our <font color="blue">operations</font> or our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our pharmacy business is subject to federal, state and local <font color="blue">government</font> laws     and regulation</td>
    </tr>
    <tr>
      <td>These include <font color="blue">local registrations</font> of pharmacies in the     states where our pharmacies are located, applicable Medicare and <font color="blue">Medicaid     </font><font color="blue">regulations</font> and <font color="blue">prohibitions against paid referrals</font> of patients</td>
    </tr>
    <tr>
      <td>Failure to     properly adhere to these and other applicable <font color="blue">regulations</font> could result in     the imposition of civil and <font color="blue">criminal penalties</font> including suspension of     payments   from  <font color="blue">government</font>  programs;  loss  of  required  <font color="blue">government</font>     certifications; loss of <font color="blue">authorizations</font> to <font color="blue">participate</font> in or <font color="blue">exclusion from</font>     <font color="blue">government</font>  <font color="blue">reimbursement</font>  programs, such as the Medicare and <font color="blue">Medicaid     </font>programs; loss of licenses; <font color="blue">significant</font> fines or <font color="blue">monetary penalties</font> for     anti-kickback law violations, submission of false claims or other failures     to meet <font color="blue">reimbursement</font> program <font color="blue">requirements</font> and <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> the     <font color="blue">continued operation</font> of our business</td>
    </tr>
    <tr>
      <td>Our  pharmacy  business  is  subject  to the <font color="blue">patient privacy</font> and other     <font color="blue">obligations</font> including corporate, pharmacy and <font color="blue">associate responsibility</font>,     <font color="blue">imposed by</font> the <font color="blue">Health Insurance Portability and Accountability Act</font></td>
    </tr>
    <tr>
      <td>As a     covered entity, we are required to implement privacy standards, train our     <font color="blue">associates</font>  on  the  permitted use and <font color="blue">disclosures</font> of protected health     information, provide a notice of privacy practice to our pharmacy customers     and permit pharmacy health customers to access and amend their records and     receive  an <font color="blue">accounting</font> of <font color="blue">disclosures</font> of protected health information</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  properly adhere to these <font color="blue">requirements</font> could result in the     imposition of civil as well as <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>Federal and state reform programs, such as healthcare reform and <font color="blue">enforcement</font>     <font color="blue">initiatives</font> of federal and state <font color="blue">government</font>s may also affect our pharmacy     business</td>
    </tr>
    <tr>
      <td>These <font color="blue">initiatives</font> include:       ·       <font color="blue">proposals designed</font> to <font color="blue">significant</font>ly reduce spending on Medicare,     Medicaid and other <font color="blue">government</font> programs;       ·       changes in <font color="blue">programs providing</font> for <font color="blue">reimbursement</font> for the cost of     <font color="blue"><font color="blue">prescription</font> drugs</font> by third party plans;       ·       the Medicare Modernization Act;       ·       <font color="blue">increased scrutiny</font> of, and <font color="blue">litigation</font> relating to, <font color="blue">prescription</font> drug     manufacturers’ pricing and marketing pactices; and       ·       <font color="blue">regulatory</font> changes relating to the <font color="blue">approval process</font> for <font color="blue">prescription</font>     drugs</td>
    </tr>
    <tr>
      <td>These <font color="blue">initiatives</font> could lead to the <font color="blue">enactment</font> of, or changes to, federal     <font color="blue">regulations</font>  and  state  <font color="blue">regulations</font>  that  could <font color="blue">adversely</font> impact our     <font color="blue">prescription</font>  drug  sales and, <font color="blue">accordingly</font>, our results of <font color="blue">operations</font>,     financial  condition  or <font color="blue">cash flow</font>s</td>
    </tr>
    <tr>
      <td>It is <font color="blue">uncertain at</font> this time what     <font color="blue">additional</font> healthcare reform <font color="blue">initiatives</font>, if any, will be implemented, or     <font color="blue">whether there will</font> be other changes in the <font color="blue">administration</font> of <font color="blue">government</font>al     <font color="blue">healthcare programs</font> or <font color="blue">interpretations</font> of <font color="blue">government</font>al policies or other     changes <font color="blue">affecting</font>       15     ______________________________________________________________________       the <font color="blue">healthcare system</font></td>
    </tr>
    <tr>
      <td>Future healthcare or <font color="blue">budget legislation</font> or other     changes, including those referenced above, may materially <font color="blue">adversely</font> impact     our <font color="blue">pharmacy sales</font></td>
    </tr>
    <tr>
      <td>Certain risks are inherent in <font color="blue">providing pharmacy services</font>; our <font color="blue">insurance may</font>     not be adequate to cover any claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td><font color="blue">Pharmacies </font>are exposed to <font color="blue">risks inherent</font> in the packaging and <font color="blue">distribution</font>     of <font color="blue">pharmaceutical</font>s and other healthcare products, such as with respect to     <font color="blue">improper filling</font> of <font color="blue"><font color="blue">prescription</font>s</font>, labeling of <font color="blue"><font color="blue">prescription</font>s</font>, adequacy of     warnings and unintentional <font color="blue">distribution</font> of <font color="blue">counterfeit drugs</font></td>
    </tr>
    <tr>
      <td>In addition,     federal and state laws that require our <font color="blue">pharmacists</font> to <font color="blue">offer counseling</font>,     without <font color="blue">additional</font> charge, to their customers about medication, dosage,     delivery systems, common side effects and other information the <font color="blue">pharmacists</font>     deem <font color="blue">significant</font> can impact our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">pharmacists</font> may also have a     duty  to  <font color="blue">warn customers</font> regarding any <font color="blue">potential negative effects</font> of a     <font color="blue">prescription</font> drug if the <font color="blue">warning could reduce</font> or negate these effects</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  maintain <font color="blue">professional <font color="blue">liability</font></font> and errors and omissions     <font color="blue">liability</font> insurance, from time to time, claims result in the payment of     <font color="blue"><font color="blue">significant</font> amount</font>s, some portions of which are not <font color="blue">funded by insurance</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that the <font color="blue">coverage limits under</font> our insurance programs will     be adequate to <font color="blue">protect us against future</font> claims, or that we will be able to     maintain this <font color="blue">insurance on</font> acceptable terms in the future</td>
    </tr>
    <tr>
      <td>Our results of     <font color="blue">operations</font>, <font color="blue">financial condition</font> or <font color="blue">cash flow</font>s may be <font color="blue"><font color="blue">adversely</font> affect</font>ed if     in the future our <font color="blue">insurance coverage proves</font> to be inadequate or unavailable     or there is an increase in <font color="blue">liability</font> for which we self-insure or we suffer     <font color="blue">reputational harm as</font> a result of an error or omission</td>
    </tr>
    <tr>
      <td>We will not be able to compete <font color="blue"><font color="blue">effective</font>ly</font> if we are unable to attract, hire     and retain qualified <font color="blue">pharmacists</font></td>
    </tr>
    <tr>
      <td>There is a <font color="blue">nationwide shortage</font> of qualified <font color="blue">pharmacists</font></td>
    </tr>
    <tr>
      <td>However, we may not     be able to attract, hire and retain enough qualified <font color="blue">pharmacists</font></td>
    </tr>
    <tr>
      <td>This could     <font color="blue"><font color="blue">adversely</font> affect</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">significant</font> <font color="blue">liability</font> should the <font color="blue">consumption</font> of any of     our products cause injury, illness or death</td>
    </tr>
    <tr>
      <td><font color="blue">Products  </font>that  we <font color="blue">sell could become</font> subject to contamination, product     tampering, mislabeling or other damage requiring us to recall our private     <font color="blue">label products</font></td>
    </tr>
    <tr>
      <td>In addition, errors in the dispensing and packaging of     <font color="blue">pharmaceutical</font>s could lead to <font color="blue">serious injury</font> or death</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font>     claims may be asserted <font color="blue">against us</font> with respect to any of the products or     <font color="blue">pharmaceutical</font>s we sell and we may be obligated to recall our private brand     products</td>
    </tr>
    <tr>
      <td>A product <font color="blue">liability</font> judgment <font color="blue">against us</font> or a <font color="blue">product recall could</font>     have a material, adverse effect on our business, <font color="blue">financial condition</font> or     results of <font color="blue">operations</font></td>
    </tr>
  </tbody>
</table>